BI 1026706

Unknown / undisclosed

Phase 2Bradykinin B1 receptorNo recent registered activity
Dormantno recent development

Evidence outlook

No registered development activity since 2019

Registered studies concluded by 2019, with no US (FDA) approval on record and no active or planned study on the registry since. No sponsor statement of discontinuation has been sourced, but the trial history should be read as archival rather than an active program.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
NCT02732951 · Boehringer Ingelheim
2016-04-14 – 2017-10-24 · Macular Edema
What this study did
Phase 1 (8)
Other / comorbidity
NCT02657408 · Boehringer Ingelheim
2016-03-11 – 2017-03-13 · Healthy
What this study did
NCT02652416 · Boehringer Ingelheim
2016-09-16 – 2016-12-09 · Healthy
What this study did
NCT02642614 · Boehringer Ingelheim
2016-01-25 – 2016-06-14 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT02513446 · Boehringer Ingelheim
2015-09-29 – 2015-11-20 · Healthy
What this study did
NCT02084511 · Boehringer Ingelheim
2014-03 – 2014-10 · Pain, Postoperative
What this study did
NCT01763333 · Boehringer Ingelheim
2013-01-08 – 2013-09-04 · Healthy
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.